STERLING DIAGNOSTICS INC

Sterling Diagnostics Inc specializes in in vitro diagnostic (IVD) reagents used primarily in laboratory settings. Their products include reagents for testing total cholesterol, urea, total bilirubin, alkaline phosphatase isoenzyme, gamma-hydroxybutyrate (GHB), glucose, creatinine, haemoglobin S (HbS), and enzymatic assays for potassium, uric acid, sodium, iron, and serum proteins. These reagents are designed to support clinical chemistry and haematology testing.

Sterling Diagnostics Inc is based in the United States, which means its devices fall under the jurisdiction of the U.S. Food and Drug Administration (FDA). Since their products are IVD reagents, they are classified under FDA regulations, with most falling into Class I or Class II categories, depending on their risk level and intended use.

Sterling Diagnostics Inc’s devices are listed in the FDA’s 510(k) premarket notification registry and the Unique Device Identifier (UDI) system. These registries ensure compliance with U.S. regulatory requirements for IVD reagents, providing transparency on their authorised products and classifications.

The FDA classifies Sterling Diagnostics Inc’s IVD reagents primarily as Class I or Class II devices. Class I devices generally pose minimal risk and may be exempt from some regulatory controls, while Class II devices require special controls to ensure safety and effectiveness. The classification depends on factors like the device’s intended use, potential risks, and the nature of the testing performed.

Listing in the FDA’s 510(k) registry indicates that the manufacturer has submitted a premarket notification to demonstrate that their IVD reagent is substantially equivalent to a legally marketed predicate device. This process ensures that the device meets FDA safety and performance standards before being authorised for commercial distribution in the U.S. market.